One Stop Target-to-Hit Platform: Cyclin-dependent kinase 2 (CDK2)
Cyclin-dependent kinase 2 (CDK2) and its respective cyclin E1 and cyclin A2 complexes are essential to driving abnormal growth processes in cancer cells, making these proteins important targets for cancer treatment. To support the discovery of novel CDK2 inhibitors, WuXi AppTec offers a comprehensive platform of biophysical and biochemical assays to accelerate hit finding and lead optimization efforts targeting CDK2. Our panel of services also includes high-quality CDK2 and CDK2-complex protein production and established X-ray crystallography protocols.
CDK2-cyclin E1_cyclin A2_platform_v2a
Related Content
Introduction: RNA-based therapies are a frontier in biomedicine, with the potential to fundamentally change treatments for a wide range of...
VIEW RESOURCEDNA-encoded libraries have become widely used in drug discovery, and several approaches for linking chemical compounds to DNA have been...
VIEW RESOURCE